Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program.

IF 4.8 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-02-06 DOI:10.1093/oncolo/oyae241

Claire Lattard, Chloé Herledan, Thibaut Reverdy, Gabriel Antherieu, Anne-Gaelle Caffin, Marie-Anne Cerfon, Magali Maire, Marine Rivat, Stéphanie France, Hervé Ghesquières, Benoit You, Gilles Freyer, Florence Ranchon, Catherine Rioufol

{"title":"Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program.","authors":"Claire Lattard, Chloé Herledan, Thibaut Reverdy, Gabriel Antherieu, Anne-Gaelle Caffin, Marie-Anne Cerfon, Magali Maire, Marine Rivat, Stéphanie France, Hervé Ghesquières, Benoit You, Gilles Freyer, Florence Ranchon, Catherine Rioufol","doi":"10.1093/oncolo/oyae241","DOIUrl":null,"url":null,"abstract":"Background: Healthcare professionals are faced with the new challenges of preventing and managing drug-related problems (DRPs) with oral anticancer therapy (OAT): side-effects, drug-drug interactions (DDIs), non-adherence, or medication errors. This study aims to assess the impact of ONCORAL, a real-life multidisciplinary care plan for cancer patients based on community and hospital follow-up, for the first OAT cycle.Methods: A prospective cohort study was conducted between October 1, 2021 and October 1, 2022 including all outpatients starting OAT treatment. During the first OAT cycle, the program consists of 6 weekly scheduled face-to-face or phone consultations to prevent and manage DRPs. Nurse and pharmacist interventions (NPIs) are realized to optimize treatments (primary outcomes). Secondary outcomes included the relative dose intensity (RDI) of the first cycle.Results: A total of 562 NPIs were performed by the ONCORAL team: that is, 87.1% of the 209 patients included, for a mean of 3.1 ± 2.2 NPIs/patient. NPIs-concerned DRPs detected by the nurse and pharmacist (346, 61.6%), symptoms and/or adverse effects reported as PROs by the patient or family (138, 24.6%), or pathway issues (78, 13.9%). Seventy-three DDIs were detected and managed during medication review, in a quarter of patients (n = 54/209), leading to the discontinuation of a daily concomitant medication in 30 cases. The mean RDI at the end of the first cycle, calculated for 209 patients, was 83.1 ± 23.9% (17.56-144.23).Conclusion: In these ambulatory cancer patients, the interest in tailored monitoring of DRPs as a whole, including the prevention and management of drug interactions in addition to symptoms and adverse effects, is highlighted.","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883160/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyae241","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Healthcare professionals are faced with the new challenges of preventing and managing drug-related problems (DRPs) with oral anticancer therapy (OAT): side-effects, drug-drug interactions (DDIs), non-adherence, or medication errors. This study aims to assess the impact of ONCORAL, a real-life multidisciplinary care plan for cancer patients based on community and hospital follow-up, for the first OAT cycle.

Methods: A prospective cohort study was conducted between October 1, 2021 and October 1, 2022 including all outpatients starting OAT treatment. During the first OAT cycle, the program consists of 6 weekly scheduled face-to-face or phone consultations to prevent and manage DRPs. Nurse and pharmacist interventions (NPIs) are realized to optimize treatments (primary outcomes). Secondary outcomes included the relative dose intensity (RDI) of the first cycle.

Results: A total of 562 NPIs were performed by the ONCORAL team: that is, 87.1% of the 209 patients included, for a mean of 3.1 ± 2.2 NPIs/patient. NPIs-concerned DRPs detected by the nurse and pharmacist (346, 61.6%), symptoms and/or adverse effects reported as PROs by the patient or family (138, 24.6%), or pathway issues (78, 13.9%). Seventy-three DDIs were detected and managed during medication review, in a quarter of patients (n = 54/209), leading to the discontinuation of a daily concomitant medication in 30 cases. The mean RDI at the end of the first cycle, calculated for 209 patients, was 83.1 ± 23.9% (17.56-144.23).

Conclusion: In these ambulatory cancer patients, the interest in tailored monitoring of DRPs as a whole, including the prevention and management of drug interactions in addition to symptoms and adverse effects, is highlighted.

查看原文本刊更多论文

对 ONCORAL 多学科社区-医院项目中接受口服抗癌治疗的门诊患者进行早期随访。

背景：医疗保健专业人员面临着预防和管理口服抗癌疗法（OAT）药物相关问题（DRPs）的新挑战：副作用、药物相互作用（DDIs）、不依从性或用药错误。本研究旨在评估 ONCORAL（基于社区和医院随访的癌症患者多学科真实护理计划）对第一个 OAT 周期的影响：方法：2021 年 10 月 1 日至 2022 年 10 月 1 日期间进行了一项前瞻性队列研究，研究对象包括所有开始接受 OAT 治疗的门诊患者。在第一个 OAT 周期中，该计划包括每周 6 次定期面对面或电话咨询，以预防和管理 DRP。实现护士和药剂师干预（NPI）以优化治疗（主要结果）。次要结果包括第一个周期的相对剂量强度（RDI）：ONCORAL团队共进行了562次NPI，占209名患者的87.1%，平均每名患者3.1±2.2次NPI。NPIs 涉及护士和药剂师发现的 DRP（346 例，61.6%）、患者或家属作为 PRO 报告的症状和/或不良反应（138 例，24.6%）或路径问题（78 例，13.9%）。四分之一的患者（n = 54/209）在用药检查过程中发现并处理了 73 例 DDI，其中 30 例患者因此停用了日常合用药物。根据计算，209 名患者在第一周期结束时的平均 RDI 为 83.1 ± 23.9% (17.56-144.23)：结论：在这些非卧床癌症患者中，对 DRP 进行有针对性的整体监测，包括预防和管理除症状和不良反应以外的药物相互作用，具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.